Article
Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations.
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Sept 2022
Zhang Guowei, Cheng Ruirui, Niu Yuanyuan, Wang Huijuan, Yan Xiangtao, Zhang Mina, Zhang Xiaojuan, Yang Jinpo, Wei Chunhua, Ma Zhiyong
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations are often associated with non-EGFR genetic alterations, which may be a reason for the poor efficacy of EGFR tyrosine kinase inhibitors (TKIs). Here we conducted this study to explore whether EGFR-TKIs combined with chemotherapy would benefit advanced lung adenocarcinoma patients with both sensitive EGFR mutation and concomitant non-EGFR genetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.